Syndax Pharmaceuticals (FRA:1T3) Other Current Payables: €6.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
20 GF Score
Price €19.50
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Other Current Payables?

Syndax Pharmaceuticals FRA:1T3 -1.42% 20 Other Current Payables is €6.5 Mil as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 20/100. The stock has 7 warning signs investors should review.

Syndax Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was €6.5 Mil.

Syndax Pharmaceuticals's quarterly Other Current Payables increased from Sep. 2025 (€5.0 Mil) to Dec. 2025 (€6.3 Mil) and increased from Dec. 2025 (€6.3 Mil) to Mar. 2026 (€6.5 Mil).

Syndax Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 (€6.6 Mil) to Dec. 2024 (€18.7 Mil) but then declined from Dec. 2024 (€18.7 Mil) to Dec. 2025 (€6.3 Mil).

Syndax Pharmaceuticals Other Current Payables Related Terms

Syndax Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Other Current Payables Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 6.63 18.66 6.30

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.94 4.15 4.99 6.30 6.45
FRA:1T3
20GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €6.5 Mil mean?
Syndax Pharmaceuticals (FRA:1T3) has a Other Current Payables of €6.5 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' Other Current Payables too high?
Syndax Pharmaceuticals' current Other Current Payables is €6.5 Mil. Overall, Syndax Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Other Current Payables compare to IOVA and GLUE?
Syndax Pharmaceuticals' Other Current Payables of €6.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Other Current Payables is €6.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Other Current Payables of €6.5 Mil. The current Other Current Payables is €6.5 Mil. Syndax Pharmaceuticals' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Other Current Payables is €6.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
20GF Score

Get the complete analysis for FRA:1T3

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.50
Price